-
2025-523658-15-00
5
2026-04-10
Obesity
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-521859-23-00
9
2026-03-31
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
-
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
-
2025-522383-33-00
5
2026-03-23
Interstitial lung diseases
-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2024-519344-32-00
9
2026-03-16
Non-small Cell Lung Cancer
-
2024-518236-36-00
5
2026-03-12
Locoregionally restricted (stage III) small intestinal neuroendocrine
-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-521117-88-00
5
2026-03-11
Cardiovascular Disease
-
2025-522232-13-00
4
2026-03-06
Sepsis-associated acute kidney injury (AKI)
-
2025-521670-34-00
5
2026-03-04
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
-
2024-511101-28-00
4
2026-02-24
Episodic Migraine
Chronic Migraine
-
2023-509860-47-00
4
2026-02-20
Ductal carcinoma in situ
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-522703-14-00
5
2026-02-17
"Moderate to severe obstructive sleep apnea (OSA) in adults living wit
-
2025-522640-41-00
4
2026-02-13
Asthma
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma